* Carisma Therapeutics Inc reported a quarterly adjusted loss of 27 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -49 cents. The mean expectation of four analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -43 cents to -17 cents per share.
* Revenue rose 158.3% to $9.20 million from a year ago; analysts expected $3.93 million.
* Carisma Therapeutics Inc's reported EPS for the quarter was a loss of 27 cents.
* The company reported a quarterly loss of $11.16 million.
* Carisma Therapeutics Inc shares had fallen by 47.4% this quarter and lost 72.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Carisma Therapeutics Inc is $8.00 This summary was machine generated from LSEG data August 8 at 01:23 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.30 -0.27 Beat
Mar. 31 2024 -0.43 -0.46 Missed
Dec. 31 2023 -0.55 -0.52 Beat
Sep. 30 2023 -0.57 -0.53 Beat
Comments